Listed

Standard Biotools Inc.: Form 10-Q for the period ended Sep 30, 2025

Filed with the SEC on Nov 4, 2025 and accepted by EDGAR at Nov 4, 2025, 16:11 ET.

Share

Management's discussion and analysis

As filed, 35,853 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited financial information and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and the audited financial information and the notes thereto included in our Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2025 (the “Annual Report”) and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 15, 2025, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.

Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Standard BioTools” the “Company,” “we,” “us,” and “our” refer to Standard BioTools Inc. and its subsidiaries.

Overview

At Standard BioTools Inc., we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more.

We have built a solid foundation supporting a differentiated portfolio of life science tools, offering broad multi-omic capabilities that drive innovation and accelerate the pace of drug development. Our solutions are designed to unlock complex biological information across plasma, single-cell and spatial proteomics, as well as genomic analyses, enabling researchers to explore disease mechanisms with unprecedented depth and precision. By integrating our advanced platforms – CyTOF™, Hyperion™, and Biomark™ – we empower scientists to generate high-content data across therapeutic areas, from immuno-oncology to neurology and infectious diseases. Each system is engineered to extract meaningful molecular signatures, providing researchers with the tools they need to decode intricate biological networks. Together, these technologies accelerate discovery, offering a comprehensive approach to understanding the complexities of health and disease.

Recent Developments

On June 22, 2025, we entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Illumina, Inc. (“Illumina”). Pursuant to the terms of the Purchase Agreement, Illumina will acquire all of the equity interests of SomaLogic, Inc. (“SomaLogic”), Sengenics Corporation LLC and Sengenics Corporation Pte Ltd, each a wholly owned subsidiary of the Company that operates our aptamer-based and functional proteomics business, including KREX, Single SOMAmer, translational and diagnostic assays (collectively, the “SomaScan Business”) (such transaction, the “Transaction”). The Transaction does not include our mass cytometry and microfluidics businesses, which are being retained by us.

Illumina has agreed to acquire the SomaScan Business for aggregate cash consideration of up to $425 million, comprising (i) an upfront payment of $350 million in cash, payable at the closing of the Transaction, subject to adjustment as set forth in the Purchase Agreement, and (ii) up to $75 million in earnout payments, payable upon the achievement of specified targets for net revenue generated from SomaScan assay services or any other SOMAmer-based assay services and sales of SOMAmer-based array kits and SOMAmer-based next-generation sequencing library preparation kits in fiscal years 2025 and 2026.

In addition, the Purchase Agreement contemplates that, at the closing of the Transaction, as additional consideration, we and Illumina will enter into (i) a royalty agreement, pursuant to which we will be entitled to a specified royalty stream on net revenues generated from sales of SOMAmer-based next-generation sequencing library preparation kits, (ii) a license agreement, pursuant to which Illumina will provide a specified license to us for the intellectual property relating to Single SOMAmers for potential development and commercialization of Single SOMAmer reagents for use in single plex affinity assays and (iii) a royalty agreement, pursuant to which we will be entitled to a specified royalty stream on net revenues generated from sales of Single SOMAmers.

The consummation of the Transaction is subject to customary closing conditions, including, among others, the expiration or termination of the applicable waiting period (and any extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. We expect the Transaction to close in the first half of 2026.

The Purchase Agreement also includes customary termination provisions, including, among others, the ability of us or Illumina to terminate the Purchase Agreement if the Transaction has not been consummated on or before March 23, 2026, subject to up to three automatic three-month extensions under certain circumstances. If the Purchase Agreement is terminated under specified circumstances, Illumina will be required to pay us a reverse termination fee in cash equal to $14.5 million.

Factors Affecting Our Performance

The following factors have been important to our business, and we expect them to impact our results of operations and financial condition in future periods:

  • Continued adoption of our services and products:
  • We have a well-established base of marquee customer and key opinion leader relationships in place, and as we grow further, we expect to win contracts with new customers and expand the scope of existing contracts with existing customers.
  • We continue to focus on growth in instrument placements which we expect to drive future growth in sales of consumables and field services.
  • We continue to enhance our single-cell and spatial proteomics offerings through continuous improvements to our proteomics instruments.
  • Total revenue may vary from period to period based on, among other things, the timing and size of new contracts, fluctuations in customer consumption of and adoption trends, ramp time and productivity of our salesforce, the impact of significant transactions, and seasonality. Failure to effectively develop and expand our sales and marketing capabilities or improve the productivity of our sales and marketing organization could harm our ability to expand our potential customer and sales pipeline, increase our customer base, and achieve broader market acceptance of our products.
  • Continued investment in growth:
  • We continue to invest significantly in our commercial infrastructure.
  • We have and expect to continue to make investments in research and development (“R&D”), including hiring employees with the necessary scientific and technical backgrounds to enable enhancements to our existing products and services and bring new products and services to market.
  • Ability to lower operating costs:
  • We continue to focus on improving operating discipline through the implementation of restructuring plans and lean Standard BioTools Business System principles to build more efficient operations and reduce costs.
  • We intend to reduce manufacturing costs, in part, by modifying our manufacturing processes to use materials and technologies that provide equal or greater quality at lower cost, improving how we manage our materials and negotiating favorable terms for our materials purchases.
  • Seasonality:
  • Our revenue can be seasonal dependent upon the procurement and budgeting cycles of many of our customers, especially government- or grant-funded customers, whose cycles often coincide with government fiscal year ends.
  • Expansion of our proteomic content:
  • To maintain our competitive advantage in the single-cell proteomics market, we plan to increase the number of protein reagents for commercial availability based on allocated funding, resource availability, and the successful validation of new reagents, with a focus on expanding our mass cytometry antibody panels and detection capabilities.
  • We continue to expand our single-cell proteomics database and artificial intelligence and machine learning analytics to drive deeper insights into cellular heterogeneity, immune profiling, and biomarker discovery, creating new value and market opportunities in translational and clinical research.

Financial Operations Overview

Revenue

We generate our revenue from the sale of products and services. We also derive revenue from collaborative arrangements, license agreements, grants, and royalties. Customers include top biopharmaceutical companies and leading academic research universities.

Product revenue

We generate product revenue from the sale of instruments and consumables. Consumables revenue is largely driven by the size of our active installed base of instruments and the level of usage per instrument.

Service revenue

Service revenue primarily consists of post-warranty service contracts, preventive maintenance plans, installation and training for our instruments. We expect the average selling prices of our products and services to fluctuate over time based on market conditions, product mix and currency fluctuations.

Cost of Revenue

Cost of product revenue

Cost of product revenue consists primarily of raw materials, equipment and production costs, salaries and other personnel costs, overhead and other direct costs related to product revenue. In addition, cost of product revenue includes amortization of developed technology, royalty costs for licensed technologies included in our products, warranty costs, provisions for excess and obsolete inventory, and stock-based compensation expense, and shipping and handling costs. Cost of product revenue is recognized in the period the related revenue is recognized. Shipping and handling costs incurred for product shipments are included in cost of product revenue in the consolidated statements of operations. Our cost of product revenue and related product margin may fluctuate depending on the capacity utilization of our manufacturing facilities in response to market conditions and the demand for our products.

Cost of service revenue

Cost of service revenue consists of raw materials and production costs, personnel-related costs, overhead and other direct costs. Cost of service revenue is recognized in the period the related revenue is recognized.

Our cost of service revenue and related service margin may fluctuate depending on the variability in material and labor costs of servicing.

Research and Development

R&D expenses consist primarily of personnel-related costs related to enhancing our technologies and supporting development and commercialization of new and existing products and services. R&D expenses also consist of laboratory supply costs, clinical study costs, consulting fees, and other allocated overhead expenses. We plan to continue to invest significantly in our R&D efforts with an expected focus on advancing our products and services. As a result, we expect R&D expenses will increase in absolute dollars in future periods and vary from period to period as a percentage of revenue.

Selling, General, and Administrative

Selling, general and administrative (“SG&A”) expenses consist primarily of personnel costs for our sales and marketing, business development, finance, legal, human resources, information technology and general management teams, as well as professional services, including legal and accounting services.

Restructuring and Related Charges

On August 28, 2025, we determined to consolidate our South San Francisco-based R&D capabilities into our Singapore facility to co-locate with our manufacturing operations and to implement a reduction in force of certain U.S. employees in our R&D function, including members of our management team. As part of this consolidation, we will vacate our South San Francisco office and transfer our headquarters to Boston, Massachusetts. We currently expect this process to be completed by December 31, 2025.

On September 13, 2025, we commenced an additional restructuring plan, which included a reduction-in-force.

Restructuring and related charges primarily consist of severance costs related to our recent reduction-in-force and facilities costs for floors we have subleased or have the intent to sublease (net of sublease income) under our facility lease in South San Francisco. These costs, including a reduction in force, are incurred to improve operational efficiency, achieve cost savings and align our workforce to the future needs of the business. When combined, these reductions-in-force impacted approximately 20% of our total global workforce.

Transaction and Integration Expenses

Transaction and integration expenses consist of costs incurred in connection with acquisition- and divestiture-related activities, including legal, advisory, accounting and other transaction-related costs including integration costs.

Bargain Purchase Gain

Bargain purchase gain represents the excess of fair value of the assets acquired and liabilities assumed over the fair value of the consideration transferred in connection with the merger with SomaLogic (the “Merger”). We determined that the bargain purchase gain was primarily attributable to a rapid decline in our stock price in the days following the announcement of the Merger, which persisted through the closing date on January 5, 2024.

Loss from Discontinued Operations

Loss from discontinued operations represents the results of operations for business components that are classified as held-for-sale and meet the criteria for discontinued operations accounting under ASC 205, Presentation of Financial Statements. This includes the operating results of the discontinued components during the periods presented.

The loss from discontinued operations is presented net of applicable income taxes and includes direct incremental costs associated with the disposal activities, such as legal, advisory, and other transaction-related costs. Any intercompany transactions between continuing and discontinued operations have been eliminated, and certain allocations of corporate overhead and shared costs previously allocated to the discontinued operations have been adjusted to reflect the costs that will be eliminated upon disposal.

Prior period amounts have been reclassified to conform to the current period presentation.

Results of Operations

The following table presents our unaudited condensed consolidated statements of operations and as a percentage of total revenue for the three and nine months ended September 30, 2025 and 2024 ($ in thousands):

Three Months Ended September 30, 2025 2024 Nine Months Ended September 30, 2025 2024
Revenue $19,552 100% $22,086 100% $61,536 100% $66,231 100%
Cost of revenue 10,068 51% 9,960 45% 30,375 49% 32,705 49%
Gross profit 9,484 49% 12,126 55% 31,161 51% 33,526 51%
Operating expenses:
Research and development 6,356 33% 6,939 31% 18,018 29% 21,791 33%
Selling, general and administrative 26,595 136% 24,466 111% 84,524 137% 75,740 114%
Restructuring and related charges 9,428 48% 2,341 11% 12,707 21% 12,374 19%
Transaction and integration expenses 43 0% 5,079 23% 1,517 2% 25,024 38%
Total operating expenses 42,422 217% 38,825 176% 116,766 190% 134,929 204%
Loss from continuing operations (32,938) (169)% (26,699) (121)% (85,605) (139)% (101,403) (153)%
Bargain purchase gain — —% — —% — —% 25,213 38%
Interest income 2,140 11% 4,794 22% 7,517 12% 16,303 25%
Interest expense (10) (0)% (853) (4)% (21) (0)% (2,744) (4)%
Other income (expense), net (2,092) (11)% 957 4% 3,438 6% (865) (1)%
Loss from continuing operations before income taxes (32,900) (168)% (21,801) (99)% (74,671) (121)% (63,496) (96)%
Income tax benefit (expense) 1,216 6% (118) (1)% 1,944 3% (270) (0)%
Net loss from continuing operations (31,684) (162)% (21,919) (99)% (72,727) (118)% (63,766) (96)%
Discontinued operations:
Loss from discontinued operations, net of tax (3,003) (15)% (5,019) (23)% (21,452) (35)% (41,047) (62)%
Net loss $(34,687) (177)% $(26,938) (122)% $(94,179) (153)% $(104,813) (158)%

25

Revenue

The following table sets forth revenue by product type, presented in dollars and as a percentage of total revenue ($ in thousands):

Product revenue: Three Months Ended September 30, 2025 2024 Year-over-Year Change $% Nine Months Ended September 30, 2025 2024 Year-over-Year Change $%
Instruments $5,095 $5,271 $(176) (3)% $16,956 $17,221 $(265) (2)%
Consumables 8,705 10,508 (1,803) (17)% 27,298 29,766 (2,468) (8)%
Total product revenue 13,800 15,779 (1,979) (13)% 44,254 46,987 (2,733) (6)%
Services and other revenue 5,752 6,307 (555) (9)% 17,282 19,244 (1,962) (10)%
Total revenue $19,552 $22,086 $(2,534) (11)% $61,536 $66,231 $(4,695) (7)%

For the three months ended September 30, 2025, total revenue declined $2.5 million, or 11%, compared to the prior year period. The decline was primarily driven by a $1.8 million decrease in consumables revenue, with services and other revenue and instruments revenue decreasing by $0.6 million and $0.2 million, respectively. The revenue decline was anticipated by management and reflects continued macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments that have impacted purchase timing and deal closure rates.

For the nine months ended September 30, 2025, total revenue declined $4.7 million, or 7%, compared to the prior year period. The decline was primarily driven by a $2.5 million decrease in consumables revenue, due to macroeconomic pressures on customer spending, including budgetary limitations and constrained funding environments. The decline was further driven by a decrease of $2.0 million in services and other revenue, as a result of lower service requirements from improved instrument reliability and timing of customer maintenance schedules.

Cost of Revenue and Gross Profit

Cost of revenue, gross profit, and gross margin were as follows ($ in thousands):

Three Months Ended September 30, 2025 2024 Year-over-Year Change $% Nine Months Ended September 30, 2025 2024 Year-over-Year Change $%
Cost of product revenue $6,728 $6,159 $569 9% $20,767 $21,775 $(1,008) (5)%
Cost of service revenue 3,340 3,801 (461) (12)% 9,608 10,930 (1,322) (12)%
Total cost of revenue $10,068 $9,960 $108 1% $30,375 $32,705 $(2,330) (7)%
Gross profit $9,484 $12,126 $(2,642) (22)% $31,161 $33,526 $(2,365) (7)%
Gross margin 48.5% 54.9% N/A (6.4)% 50.6% 50.6% N/A 0.0%

For the three months ended September 30, 2025, gross profit decreased $2.6 million, or 22%, compared to the prior year period, primarily due to revenue decline.

For the nine months ended September 30, 2025, gross profit decreased $2.4 million, or 7%, compared to the prior year period, primarily due to revenue decline.

Operating Expenses

Operating expenses were as follows ($ in thousands):

Three Months Ended September 30, 2025 2024 Year-over-Year Change $% Nine Months Ended September 30, 2025 2024 Year-over-Year Change $%
Research and development $6,356 $6,939 $(583) (8)% $18,018 $21,791 $(3,773) (17)%
Selling, general and administrative 26,595 24,466 2,129 9% 84,524 75,740 8,784 12%
Restructuring and related charges 9,428 2,341 7,087 303% 12,707 12,374 333 3%
Transaction and integration expenses 43 5,079 (5,036) (99)% 1,517 25,024 (23,507) (94)%
Total operating expenses $42,422 $38,825 $3,597 9% $116,766 $134,929 $(18,163) (13)%

Research and Development

For the three months ended September 30, 2025, R&D expense decreased by $0.6 million, or 8%, compared to the prior year period. The reduction in R&D expense was primarily driven by the deferral of long-term R&D projects, which reduced personnel and material costs.

For the nine months ended September 30, 2025, R&D expense decreased $3.8 million, or 17%, compared to the prior year period. The reduction reflects restructuring activities undertaken during 2024 and 2025, which reduced personnel-related expenses by $1.7 million. Additionally, long-term R&D projects were deferred, which reduced material and supply costs by $1.7 million and consulting costs by $0.6 million.

Selling, General and Administrative

For the three months ended September 30, 2025, SG&A expense increased by $2.1 million, or 9%, compared to the prior year period. This increase primarily reflects the classification of the SomaScan business as discontinued operations. Following this classification, certain personnel-related costs and corporate overhead costs that previously supported both business segments now remain with continuing operations, as these shared services and infrastructure costs cannot be proportionally allocated to discontinued operations. The increase in these residual costs compared to the prior year period primarily reflects infrastructure expansion during the intervening period, which created a larger base of shared costs at the time of discontinuation.

For the nine months ended September 30, 2025, SG&A expense increased $8.8 million, or 12%, compared to the prior year period. The increase primarily reflects $6.6 million in stock-based compensation expense due to accelerated vesting associated with headcount reductions, $5.6 million in personnel and infrastructure costs, $1.6 million in depreciation and amortization expense, and $1.1 million in materials and supplies expense. These increases were partially offset by a $5.6 million decrease in consulting fees.

Restructuring and Related Charges

Restructuring and related charges for the three and nine months ended September 30, 2025 increased by $7.1 million and $0.3 million, or 303% and 3%, respectively, compared to the prior year periods. The increase in both periods was primarily driven by an increase in severance and other benefits paid in connection with a reduction of our workforce during the three months ended September 30, 2025.

Transaction and Integration Expenses

Transaction and integration expenses for the three and nine months ended September 30, 2025 decreased by $5.0 million and $23.5 million, or 99% and 94%, respectively, compared to the prior year periods. The decrease in both periods was due significant legal, advisory, accounting, and integration expenses incurred in connection with the Merger during the nine months ended September 30, 2024, the majority of which were one-time in nature. We expect to incur additional transaction and integration expenses in connection with current and future transactions.

Bargain purchase gain

Bargain purchase gain decreased by $25.2 million, or 100%, for the nine months ended September 30, 2025 compared to the prior year period. The bargain purchase gain recognized during the nine months ended September 30, 2024 was due to the consummation of the Merger, which resulted in the fair value of assets acquired and liabilities assumed exceeding the fair value of the consideration transferred due to a decline in our stock price following the announcement of the Merger. The Company did not recognize any gains on bargain purchases of businesses during the three or nine months ended September 30, 2025.

Interest Income

Interest income decreased by $2.7 million and $8.8 million, or 55% and 54%, for the three and nine months ended September 30, 2025, respectively, compared to the prior year periods. The decrease in both periods was primarily due to a reduction in the interest earned on balances of money market funds and investments. The interest earned on money market funds and investments decreased due to lower account balances and interest rates during the three and nine months ended September 30, 2025.

Interest Expense

Interest expense decreased by $0.8 million and $2.7 million, or 99% and 99%, for the three and nine months ended September 30, 2025, respectively, compared to the prior year periods. During 2024, we fully repaid our then-outstanding term loan facility, as well as the balance on convertible notes issued during 2019. As a result, we had no material debt outstanding during the three and nine months ended September 30, 2025, which resulted in negligible interest expense for the periods.

Other Income (Expense), net

Other income (expense), net decreased by $3.0 million for the three months ended September 30, 2025 and increased by $4.3 million for the nine months ended September 30, 2025, compared to the prior year periods. The decrease in the three-month period was primarily due to foreign currency transaction losses on intercompany receivables denominated in foreign currencies, while the increase in the nine-month period was primarily driven by foreign currency transaction gains on these receivables. The nine-month period also benefited from a $3.4 million gain from a decrease in the fair value of our contingent consideration liability.

Income Tax Expense

We recorded an income tax benefit of $1.2 million and income tax expense of $0.1 million in the three months ended September 30, 2025 and 2024, respectively. We recorded an income tax benefit of $1.9 million and income tax expense of $0.3 million for the nine months ended September 30, 2025 and 2024, respectively.

The favorable impact to our tax provisions reflect the effect of our foreign operations, which reported lower pre-tax income in the three and nine months ended September 30, 2025 compared to the same periods in 2024.

Our effective tax rates for both periods differ from the 21% U.S. Federal statutory tax rate primarily due to valuation allowances recorded against deferred tax assets on domestic losses and the tax rate differences between the United States and foreign countries.

Loss from discontinued operations

Loss from discontinued operations decreased by $2.0 million and $19.6 million, or 40% and 48%, for the three and nine months ended September 30, 2025, respectively, compared to the corresponding periods in 2024. The decreases in loss from discontinued operations were primarily due to reductions in operating expenses as a result of restructuring activities undertaken in 2024, which reduced personnel-related costs and other operating expenses within the SomaScan Business.

Liquidity and Capital Resources

We have experienced operating losses since inception and have an accumulated deficit of $1,279.8 million as of September 30, 2025. To date, we have funded our operating losses primarily through acquisitions, equity offerings, term loans, convertible notes and redeemable preferred stock. Our ability to fund future operations and meet debt covenant requirements will depend upon our level of future revenue and operating cash flow and our ability to access additional funding through acquisitions, divestitures, equity offerings, or issuances of debt instruments.

Our liquidity and capital requirements depend upon many factors, including market acceptance of our products and services; effectiveness of our business improvement initiatives and restructuring programs; costs of supporting sales growth, product quality, R&D and capital expenditures, including our enterprise resource planning upgrade; and costs and timing of acquiring other businesses, assets or technologies or disposing of our businesses, assets or technologies.

We continually evaluate our liquidity requirements considering our operating needs, growth initiatives and capital resources. We expect that our existing liquidity and sources of capital will be sufficient to support our operations for at least the next 12 months from the filing date of this Quarterly Report on Form 10-Q.

Sources of Liquidity

Our principal sources of liquidity are cash, cash equivalents and investments. Our collective balances of cash, cash equivalents and investments were $214.4 million and $292.9 million at September 30, 2025 and December 31, 2024, respectively.

Capital Resources and Commitments

We have entered into arrangements that serve as sources of capital and the associated contractual agreements may result in firm or contingent obligations of us. In addition to our common stockholders’ equity, our sources of capital have historically included debt and operating leases. Our operating lease arrangements require cash repayment, and our convertible debt contains rights that may result in their conversion to our common stock prior to maturity. However, as of September 30, 2025, we have repaid the majority of our traditional debt obligations and no longer maintain access to credit facilities. Accordingly, our ongoing sources of capital are primarily limited to equity and cash generated from operations.

We also enter into contractual and legally binding commitments to purchase goods. Most of these contracts are cancellable with little or no notice or penalty. However, once a vendor has incurred costs to fulfill a contract with us, and which costs cannot be otherwise deployed, we are liable for those costs upon cancellation.

Cash Flow Activity

Our cash flow summary was as follows ($ in thousands):

Cash flow summary: Nine Months Ended September 30, 2025 2024
Net cash used in operating activities $(73,153) $(129,395)
Net cash provided by investing activities 35,449 337,448
Net cash used in financing activities (50) (48,096)
Effect of foreign exchange rate fluctuations on cash and cash equivalents 942 (518)
Net (decrease) increase in cash, cash equivalents and restricted cash $(36,812) $159,439

We derive cash flows from operations primarily by collecting amounts due from sales of our products and services, and fees earned under our product development and license agreements. Our cash flows from operating activities are also significantly influenced by our use of cash for operating expenses and working capital to support the business. We have historically experienced negative cash flows from operating activities as we have expanded our business and built our infrastructure, domestically and internationally.

In the nine months ended September 30, 2025, we used $43.3 million of net proceeds from the sales and maturities of investments to help fund $73.2 million of net cash used in operating activities. We did not repurchase any common stock or repay any debt during the nine months ended September 30, 2025.

In the nine months ended September 30, 2024, we used $62.4 million of net proceeds from the sales and maturities of investments to help fund $129.4 million of net cash used in operating activities, $40.5 million of common stock repurchases under the 2024 Stock Repurchase Program, and $8.2 million of repayments on our term loan facility and convertible notes issued in 2014.

Operating Activities

Net cash used in operating activities decreased by $56.2 million for the nine months ended September 30, 2025 compared to the same period in 2024. The decrease in cash use is due to a decrease in operating expenses for the nine months ended September 30, 2025 compared to the same period in 2024, resulting from the completion of restructuring activities during 2024.

Investing Activities

Net cash provided by investing activities was $35.4 million for the nine months ended September 30, 2025, compared to $337.4 million for the same period in 2024. The activity for the nine months ended September 30, 2025 is primarily due to $43.3 million of proceeds from sales and maturities of investments, net of purchases, partially offset by purchases of property and equipment of $7.8 million. In contrast, the net cash provided for the nine months ended September 30, 2024 reflects $280.0 million of cash acquired in the Merger, along with $62.4 million of proceeds from sales and maturities of investments, net of purchases.

Financing Activities

Cash used in financing activities was less than $0.1 million for the nine months ended September 30, 2025 compared to $48.1 million for the nine months ended September 30, 2024. During the nine months ended September 30, 2024, we executed $40.5 million of common share repurchases under the 2024 Stock Repurchase Program and made $8.2 million of payments on the Company's term loan and convertible notes issued in 2014. We did not repurchase any common shares or repay any debt during the nine months ended September 30, 2025.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations are based on our unaudited condensed consolidated financial statements and related notes, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the use of estimates and assumptions to determine the value of the assets, liabilities, revenues and expenses reported on the condensed consolidated balance sheets and statements of operations. We develop these estimates after considering historical transactions, the current economic environment and various other assumptions considered reasonable under the circumstances. Actual results may differ materially from these estimates and judgments. Accounts that rely heavily on estimated information to determine their values include revenue, trade receivables, inventories, right-of-use assets, lease liabilities and income tax liabilities (assets). Refer to Item 7 in our Annual Report for additional information regarding our critical accounting policies and estimates.

Recent Accounting Pronouncements

From time to time, new accounting standards are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

Market risk

As filed, 2,183 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates and foreign exchange rates, as well as, to a lesser extent, inflation and capital market risk.

Interest Rate Risk

We are exposed to interest rate risk in the ordinary course of our business. Our cash and cash equivalents are comprised of funds held in checking accounts and money market accounts. The primary objective of our cash investment activities is to preserve our capital for the purpose of funding operations.

Foreign Currency Risk

Due to our operations outside of the United States, we are exposed to market risk related to changes in foreign currency exchange rates. Historically, we have not hedged our foreign currency exposure. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, our financial conditions, our results of operations or our cash flows. For the nine months ended September 30, 2025, the Company recognized $3.2 million of foreign currency exchange gains due to changes in foreign currency exchange rates. For the three and nine months ended September 30, 2024, foreign currency exchange rates did not have a material impact on our historical financial position, our business, our financial condition, our results of operations or our cash flows.

Inflation Risk

We do not believe that inflation had a material effect on our business, financial condition, results of operations or cash flows in the last two years. If global inflation trends continue, we expect appreciable increases in labor and other operating costs.

Capital Market Risk

We generate our revenue from the sale of products and services and from collaborative arrangements, license agreements, grants, and royalties, but we may in the future raise funds through other sources. One possible source of funding is through further securities offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price among other things.

Controls and procedures

As filed, 2,680 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2025, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.

Risk factors

As filed, 1,129 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We operate in a rapidly changing environment that involves numerous uncertainties and risks. You should carefully consider the risk factors discussed in Part I Item 1A “Risk Factors” in our Annual Report and Part II Item 1A “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which could materially affect our business, financial condition or results of operations. The risks in our Annual Report and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 are not the only ones we face. Our business is also subject to the risks that affect many other companies, such as employee relations, general economic conditions, global geopolitical events and international operations. Further, additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. If any of these risks occur, our business, results of operations or financial condition could suffer, the trading price of our securities could decline, and you may lose all or part of your investment.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-07-01 to 2025-09-30$19.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2025-01-01 to 2025-09-30$61.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2025-07-01 to 2025-09-30$10.1mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue9 months2025-01-01 to 2025-09-30$30.4mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2025-07-01 to 2025-09-30$9.5mus-gaap:GrossProfit
Gross profit9 months2025-01-01 to 2025-09-30$31.2mus-gaap:GrossProfit
Research and development3 months2025-07-01 to 2025-09-30$6.4mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2025-01-01 to 2025-09-30$18.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-07-01 to 2025-09-30$26.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2025-01-01 to 2025-09-30$84.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-07-01 to 2025-09-30−$32.9mus-gaap:OperatingIncomeLoss
Operating income9 months2025-01-01 to 2025-09-30−$85.6mus-gaap:OperatingIncomeLoss
Income tax3 months2025-07-01 to 2025-09-30−$1.2mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2025-01-01 to 2025-09-30−$1.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-07-01 to 2025-09-30−$34.7mus-gaap:NetIncomeLoss
Net income9 months2025-01-01 to 2025-09-30−$94.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-07-01 to 2025-09-30−$0.09us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2025-01-01 to 2025-09-30−$0.25us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-07-01 to 2025-09-30−$0.09us-gaap:EarningsPerShareBasic
Basic EPS9 months2025-01-01 to 2025-09-30−$0.25us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-07-01 to 2025-09-30382,630,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2025-01-01 to 2025-09-30380,468,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2025-01-01 to 2025-09-30−$73.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2025-01-01 to 2025-09-30$7.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases9 months2025-01-01 to 2025-09-30$0us-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2025-09-30$129.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-09-30$472.4mus-gaap:AssetsCurrent
Total assetsAt period end2025-09-30$539.6mus-gaap:Assets
Current liabilitiesAt period end2025-09-30$108.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-09-30$140.0mus-gaap:Liabilities
Shareholders' equityAt period end2025-09-30$399.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-25-264695. Last ingested by Listed: Nov 5, 2026, 21:16 ET. Listed shows no prices and gives no investment advice.